详情页

当前位置：首页 > 详情页

Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?

11| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Fourth Hosp Hebei Med Univ, Hebei Clin Res Ctr Radiat Oncol, Dept Radiat Oncol, Shijiazhuang 050000, Hebei, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept VIP Med Serv & Radiat Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [3]Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc,Dept Radiat Oncol, Tianjin, Peoples R China

出处：

DOI：

ISSN：

关键词： adjuvant therapy concurrent chemoradiotherapy esophageal squamous cell carcinoma immunotherapy

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学 3 区呼吸系统

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区呼吸系统

JCR分区：

出版当年[2022]版：

Q3 ONCOLOGY Q3 RESPIRATORY SYSTEM

最新[2024]版：

Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 2.3 最新[2024版] 2.7 最新五年平均 2.9 出版当年[2022版] 3.1 出版当年五年平均 3.223 出版前一年[2021版] 2.3 出版后一年[2023版]

第一作者：

第一作者机构： [1]Fourth Hosp Hebei Med Univ, Hebei Clin Res Ctr Radiat Oncol, Dept Radiat Oncol, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, 050000, China

通讯作者：

通讯机构： [1]Fourth Hosp Hebei Med Univ, Hebei Clin Res Ctr Radiat Oncol, Dept Radiat Oncol, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, 050000, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma [2]Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial [3]Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy [4]First-line induction or consolidation chemotherapy combined with concurrent chemoradiotherapy for esophageal squamous cell carcinoma [5]A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma [6]Salvage Re-Irradiation Versus-Concurrent Chemoradiotherapy For Esophageal Squamous Cell Carcinoma Patients With Locally Relapse After Definitive Chemoradiotherapy [7]Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma. [8]Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery [9]Factors on prognosis in patients of stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy [10]Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical trial